Cerebral dopamine neurotrophic factor - Herantis Pharma

Drug Profile

Cerebral dopamine neurotrophic factor - Herantis Pharma

Alternative Names: CDNF; CDNF-protein; HER-902

Latest Information Update: 16 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Helsinki
  • Developer Herantis Pharma; Renishaw
  • Class Antiparkinsonians; Nerve growth factors; Neuroprotectants
  • Mechanism of Action Neuron modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Amyotrophic lateral sclerosis
  • New Molecular Entity Yes
  • Available For Licensing Yes - Alzheimer's disease

Highest Development Phases

  • Phase I/II Parkinson's disease
  • Preclinical Alzheimer's disease; Amyotrophic lateral sclerosis

Most Recent Events

  • 27 Sep 2017 Phase-I/II clinical trials in Parkinson's disease in Finland (Intracerebral) (EudraCT-2015-004175-73; NCT03295786)
  • 27 Sep 2017 Phase-I/II clinical trials in Parkinson's disease in Sweden (Intracerebral) (NCT03295786)
  • 01 Jun 2017 Finnish Medicines Agency approves IND application for Cerebral dopamine neurotrophic factor in Parkinson's disease in Finland
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top